Table 1. PBC patients and tumor clinicopathological viariables.
| Characteristics | No. of patients | % |
| Age (years) | ||
| ≤35 | 29 | 11.6 |
| >35 | 220 | 88.4 |
| Menopausal status | ||
| Premenopausal | 143 | 57.4 |
| Postmenopausal | 106 | 42.6 |
| Stage | ||
| I | 3 | 1.2 |
| II | 35 | 14.1 |
| III | 133 | 53.4 |
| Undetermined | 59 | 23.7 |
| Tumor size (cm) | ||
| ≤2 | 70 | 28.1 |
| >2 | 160 | 64.3 |
| Undetermined | 19 | 7.6 |
| Lymphonodes status | ||
| Negative | 119 | 47.8 |
| Positive | 126 | 50.6 |
| Unknown | 4 | 1.6 |
| ER status | ||
| Negative | 93 | 37.3 |
| Positive | 152 | 61.1 |
| Unknown | 4 | 1.6 |
| PR status | ||
| Negative | 111 | 44.6 |
| Positive | 134 | 53.8 |
| Unknown | 4 | 1.6 |
| Tissue HER2(IHC/FISH) | ||
| Negative | 183 | 73.5 |
| Positivea | 61 | 24.5 |
| Unknown | 5 | 2.0 |
| Adjuvant systematic treatment | ||
| Adjuvant CT | 153 | 61.4 |
| Endocrine therapy | 90 | 36.1 |
| Only endocrine therapy | 9/90 | 10.0 |
| Endocrine therapy after CT | 81/90 | 90.0 |
a
IHC 3+, IHC2+ and FISH amplified.
ER, estrogen receptor; PR, progesterone receptor; CT, chemotherapy; HER2, human epidermal growth factor receptor-2; ECD, extracellular domain; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.